The short answer
HER2-low is a biomarker result. It means a lower level of HER2 protein expression on testing. In some cancers, biomarker results can help guide targeted therapy, immunotherapy, or clinical trial options, but the result only matters in context.
HER2-low is a biomarker or molecular result, not a treatment decision by itself.
It can be relevant in some breast cancer reports and treatment discussions.
A positive result may or may not change treatment depending on cancer type, stage, prior treatment, and available options.
Ask whether the result is from tumor testing, blood testing, inherited genetic testing, or another method.
Choose how you want to understand this
The full explanation.
A category that did not used to exist
For years, breast cancer testing sorted tumors into two groups. HER2-positive meant the cancer made too much of a growth-driving protein called HER2. HER2-negative meant it did not make enough to matter. HER2-low is a newer category carved out of what used to be lumped into "HER2-negative." It exists for a specific reason. A newer drug turned out to work against HER2 levels doctors previously considered too low to bother targeting. It is best understood as a label about the test result, not as a separate kind of breast cancer.
What HER2-low means on your report
Pathologists score HER2 with a test called IHC, on a scale from 0 to 3+. A score of 0 means essentially no HER2 staining. Doctors now sometimes call this HER2-zero. A score of 3+ means strong staining. Doctors call this HER2-positive. HER2-low sits in between. It includes a score of 1+. It also includes a score of 2+, when a follow-up test called FISH confirms there are no extra copies of the HER2 gene. In practical terms, HER2-low means the stain picked up a small amount of HER2. That is not enough to qualify as HER2-positive, but it is more than nothing.
Two things are worth knowing about that line. The first is that the boundary between a 0 and a 1+ is a judgement call made by eye down a microscope, and pathologists do not always agree on it. The stain was designed to find strong HER2 signals, not faint ones. Repeating the test, or testing a different piece of tissue, can move a result across the line. The second is that the categories have since been split further. In January 2025 the FDA added HER2-ultralow, defined as IHC 0 with some membrane staining, alongside HER2-low, defined as IHC 1+ or IHC 2+ with a negative ISH test. Ask for the wording your pathologist actually used, and the IHC score itself, rather than a category name passed along second hand.
Why this distinction went from meaningless to important
Before 2022, HER2-low made no practical difference. Tumors in this category were treated the same as HER2-negative ones. Treatment used chemotherapy, hormone therapy, or both, depending on other features. That changed with a drug called trastuzumab deruxtecan. It was tested in a major trial called DESTINY-Breast04. It combines a HER2-targeting antibody with a chemotherapy payload. This gets delivered directly to cells with even small amounts of HER2 on their surface. The trial showed real benefit for people with HER2-low metastatic breast cancer. This group previously had no HER2-targeted option at all. This is why a category that used to be a footnote is now something worth knowing precisely.
What HER2-low does not mean
HER2-low does not mean your cancer will behave like HER2-positive cancer, and it is not treated with the standard HER2-positive drugs such as trastuzumab alone. Nor is it a distinct biological subtype in the way that hormone-receptor status is; it is a measurement band drawn around which patients did well in particular drug trials, and the bands have moved once already. It also does not guarantee you a particular drug: eligibility depends on hormone receptor status, on what treatment you have already had, and on the wording of the current approval. It mainly matters once a cancer has become metastatic, or come back after earlier treatment. If your cancer is early-stage, your HER2-low result may matter less right now. It is still worth having on record, in case it becomes relevant later.
What to ask your team
- Is my tumor HER2-zero, HER2-low, or HER2-positive, and how was that determined?
- What exact IHC score is on my report, and does it read as 0, ultralow, low or positive?
- Given my hormone receptor status and my previous treatment, does that score open up an option such as trastuzumab deruxtecan?
- If the score sat close to a boundary, would retesting or testing another sample be worthwhile?
- Would this result be retested if my cancer progresses or returns?
- How does my HER2 status combine with my hormone receptor status to shape my overall treatment plan?
Sources
- National Cancer Institute — Fam-trastuzumab deruxtecan-nxki
- U.S. Food and Drug Administration — FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer
- College of American Pathologists — HER2-Low Breast Carcinoma
- New England Journal of Medicine — Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Words to know
Tap any term to see what it means.
Common questions
What is HER2-low?
HER2-low means a lower level of HER2 protein expression on testing. It is one type of result that may appear on a biomarker, molecular, genomic, or pathology report.
Can it affect treatment?
Sometimes. Certain biomarkers can point toward targeted therapy, immunotherapy, or a clinical trial, but the same result can mean different things in different cancers.
What should I ask my oncologist?
Ask whether the result is actionable for your cancer, whether a matched treatment exists, and whether a trial is relevant.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Look up more plain-language explanations for report wording.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Knowledge Check
0 of 3 answered
This self-assessment checks understanding of educational content only. It is not medical advice.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-13 what this meansLast updated: 2026-08-19Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Editorial review complete. This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Editorial review complete — This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share